358 related articles for article (PubMed ID: 17296440)
1. Matrix metalloproteinase expression in the recurrence of superficial low grade bladder transitional cell carcinoma.
Choi YD; Cho NH; Ahn HS; Cho KS; Cho SY; Yang WJ
J Urol; 2007 Mar; 177(3):1174-8. PubMed ID: 17296440
[TBL] [Abstract][Full Text] [Related]
2. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
[TBL] [Abstract][Full Text] [Related]
3. [Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) expression in superficial transitional cell bladder carcinoma].
Guo ZH; Mei H; Huang J; Li SY
Ai Zheng; 2003 Mar; 22(3):307-9. PubMed ID: 12654193
[TBL] [Abstract][Full Text] [Related]
4. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
[TBL] [Abstract][Full Text] [Related]
5. Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder.
Elsamman E; Fukumori T; Kasai T; Nakatsuji H; Nishitani MA; Toida K; Ali N; Kanayama HO
BJU Int; 2006 Jun; 97(6):1202-7. PubMed ID: 16686711
[TBL] [Abstract][Full Text] [Related]
6. P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer.
Ito M; Nishiyama H; Kawanishi H; Matsui S; Guilford P; Reeve A; Ogawa O
J Urol; 2007 Sep; 178(3 Pt 1):1073-9. PubMed ID: 17644138
[TBL] [Abstract][Full Text] [Related]
7. Micro-array analysis of the effect of post-transurethral bladder tumor resection urine on transforming growth factor-beta1 dependent gene expression in transitional cell carcinoma.
Zhang G; Cao Y; Xu Y; See WA
Urol Oncol; 2005; 23(6):413-8. PubMed ID: 16301119
[TBL] [Abstract][Full Text] [Related]
8. [Smad4 and TGF-beta1 expression and clinical significance in bladder transitional cell carcinoma].
Tang ZY; Yang LY; Zhang YJ; Peng KL; Qi L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Jun; 31(3):363-6. PubMed ID: 16859125
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
Yang TB; Zeng FH; Sun ZQ
Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
[TBL] [Abstract][Full Text] [Related]
10. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
Dekairelle AF; Tombal B; Cosyns JP; Gala JL
Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
[TBL] [Abstract][Full Text] [Related]
12. [The significance of platelet-derived endothelial cell growth factor mRNA expression in superficial bladder cancer].
Li G; Zhang YF; Ding Q; Yan CY; Wen DG
Zhonghua Wai Ke Za Zhi; 2004 Apr; 42(8):478-81. PubMed ID: 15144643
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma.
Messing EM
Cancer Res; 1990 Apr; 50(8):2530-7. PubMed ID: 1690599
[TBL] [Abstract][Full Text] [Related]
14. Expression of platelet-derived endothelial cell growth factor in bladder carcinoma.
Mizutani Y; Okada Y; Yoshida O
Cancer; 1997 Mar; 79(6):1190-4. PubMed ID: 9070497
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder.
Das K; Zhao Y; Sugiono M; Lau W; Tan PH; Cheng C
Urol Oncol; 2007; 25(4):317-21. PubMed ID: 17628298
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the gene expression of SPARC and its prognostic value for bladder cancer.
Yamanaka M; Kanda K; Li NC; Fukumori T; Oka N; Kanayama HO; Kagawa S
J Urol; 2001 Dec; 166(6):2495-9. PubMed ID: 11696817
[TBL] [Abstract][Full Text] [Related]
17. Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder.
Liu L; Zhu D; Gao R; Guo H
Urol Int; 2008; 81(1):72-6. PubMed ID: 18645275
[TBL] [Abstract][Full Text] [Related]
18. DNA content and proliferation activity in superficial transitional cell carcinoma of the bladder.
Pantazopoulos D; Ioakim-Liossi A; Karakitsos P; Aroni K; Kakoliris S; Kanavaros P; Kyrkou KA
Anticancer Res; 1997; 17(1B):781-6. PubMed ID: 9066620
[TBL] [Abstract][Full Text] [Related]
19. Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Wolff I; Schostak M; Tabiti K; Müller M; Miller K; Schrader M
Cancer Lett; 2007 Jan; 245(1-2):121-6. PubMed ID: 16473461
[TBL] [Abstract][Full Text] [Related]
20. Expression of cyclooxygenase-2, vascular endothelial growth factor and matrix metalloproteinase-2 in patients with primary laryngeal carcinoma: a tissue microarray study.
Dong P; Li X; Yu Z; Lu G
J Laryngol Otol; 2007 Dec; 121(12):1177-83. PubMed ID: 17888194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
